Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

S&U trending ahead of FY24, awaits Supreme Court verdict

(Sharecast News) - Specialist lender S&U said on Wednesday that its optimism in its FY results was "gradually and clearly being justified" by the group's recent performance, particularly over the past two months. S&U said it was now tracking "ahead of 2024 at half-year and accelerating from there", driven by improved sales numbers, stronger collections at Advantage and the "tapering" of additional professional and regulatory costs.

The London-listed group stated net receivables for its motor finance unit, Advantage, were £273.0m, down from £337.0m the previous year but trending "above budget".

However, S&U pointed out that it was still waiting for the Supreme Court to deliver its verdict on whether it was unlawful for banks to pay a commission to car dealers without the customer's informed consent. S&U said a "clear and pragmatic decision" would provide "much-needed clarity" to the sector and support Downing Street's mandate of improving Britons' access to credit.

Aspen, S&U's property lender, was said to have continued to "power ahead", with record profits in Q1 and a 7% year-on-year increase in receivables, despite higher-than-expected repayments of more than £57.0m.

Chairman Anthony Coombs said: "Throughout our history, S&U's people have skilfully adapted to new market conditions and opportunities. This is evident now at both Advantage and Aspen and has happily continued in May.

"Assuming a stable and supportive environment from policymakers, regulators, and the Courts, we believe these efforts will translate into improved profitability this year and in the future."

As of 0900 BST, S&U shares were down 2.63% at 1,480.0p.

Reporting by Iain Gilbert at Sharecast.com

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.